Core Insights - The prevalence of insomnia among adults in China is increasing, with the number of affected individuals expected to reach 300 million by 2024 and 330 million by 2030 [1] - The sleep economy market in China is expanding, with the insomnia medication market projected to grow from 12.28 billion yuan in 2021 to 15.12 billion yuan by 2025, and 21.19 billion yuan by 2030 [1] - New dual orexin receptor antagonists (DORAs) have been approved for the Chinese market, targeting the general population suffering from insomnia [1][2] Market Dynamics - The traditional insomnia medication market, primarily consisting of benzodiazepines, has seen rapid growth, with sales in sample hospitals reaching 1.641 billion yuan in 2021 [1] - Despite the growth, a significant portion of the insomnia population remains untreated, with over 40% of the population experiencing sleep issues and less than 30% seeking medical help [2] - DORAs present a new opportunity as they do not fall under the strict regulations of controlled substances, making them more accessible to the general public [2] Product Development - Two new DORA medications, Lemborexant and Daridorexant, were approved in China in May and June 2023, respectively, and are now available on e-commerce platforms and retail pharmacies [3] - Both medications have applied for inclusion in the national medical insurance directory, indicating potential for price negotiations and broader access [3] - Current clinical trials for DORA medications include YZJ-1139 and HEC-83518, indicating ongoing innovation in the insomnia treatment space [3] Competitive Landscape - The insomnia medication market is competitive, with various options available, including traditional medications and newer alternatives like melatonin receptor agonists [4] - Agomelatine, a melatonin receptor agonist, has shown significant sales growth, reaching 640 million yuan in 2022, with a year-on-year increase of 29.6% [4] - The dual orexin receptor antagonists are positioned to address unmet needs in the insomnia treatment market, particularly for patients who have not previously used related medications [3][4] Treatment Approaches - Non-pharmacological interventions such as relaxation training, deep breathing, meditation, and aerobic exercise are recommended for occasional insomnia, reducing the need for medication [5] - For persistent insomnia, a thorough evaluation by a specialist is advised to rule out other underlying issues before considering medication [5]

Group 1 - The core viewpoint of the news is that the innovative insomnia drug Daridorexant (brand name: Kewico®) developed by the company in collaboration with Idorsia has been officially approved for marketing in China, enhancing patient access and supporting long-term use [1][2] - Daridorexant targets the orexin pathway in the hypothalamus, which is crucial for wakefulness, contrasting with traditional insomnia medications that act on GABA receptors to induce sedation [1] - The drug has shown significant clinical trial results, including reduced time to sleep onset and decreased wake time after sleep, with no serious adverse reactions reported during treatment [1] Group 2 - Daridorexant is the only DORA (Dual Orexin Receptor Antagonist) insomnia medication approved by the European Medicines Agency that improves daytime functioning, and it has been approved in 11 countries including the US, UK, and Japan [2] - The company entered into an exclusive licensing agreement with Idorsia for the development and commercialization of Daridorexant in the Greater China region, recognizing its market potential [2] - A supplementary agreement was reached between Idorsia and the company, involving a one-time cash payment of $50 million and adjustments to sales milestone payments and royalty rates, aimed at facilitating the commercialization of Daridorexant [2]